Rakeb Tafesse
YOU?
Author Swipe
View article: Second Generation Tiancimycin-Based Antibody–Drug Conjugates Enabled by Highly Efficient Semi-synthetic Approach Specifically Targeting B-Cell Malignancies
Second Generation Tiancimycin-Based Antibody–Drug Conjugates Enabled by Highly Efficient Semi-synthetic Approach Specifically Targeting B-Cell Malignancies Open
Antibody-drug conjugates (ADCs) are advanced cancer therapeutics that combine an antibody-based delivery system with a cytotoxic payload through chemical linkers. Anthraquinone-fused enediyne (AFE) natural products, such as tiancimycins (T…
View article: Siglec-6 as a therapeutic target for cell migration and adhesion in chronic lymphocytic leukemia
Siglec-6 as a therapeutic target for cell migration and adhesion in chronic lymphocytic leukemia Open
Siglec-6 is a lectin receptor with restricted expression in the placenta, mast cells and memory B-cells. Although Siglec-6 is expressed in patients with chronic lymphocytic leukemia (CLL), its pathophysiological role has not been elucidate…